Use of β-Adrenergic Blocking Agents in Arterial Hypertension

  • E. Alegría Ezquerra
  • J. A. Arrieta
  • R. Huguet
  • J. Barba
  • D. Martinez-Caro
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 81)

Abstract

At present, antihypertensive treatment usually constitutes a preventive measure rather than a true therapeutic necessity. This is obviously due to the fact that arterial hypertension (AH) is one of the main risk factors for ischemic heart disease.

Keywords

Atrioventricular Block Raynaud Phenomenon Insulin Hypoglycemia Arterial Hypertension Patient Peripheral Arterial Insufficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    World Health Organization: Arterial hypertension. Report of an expert committee. WHO Technical Report Series No 628,1978; 1–57.Google Scholar
  2. 2.
    Meier M, Orwin J, Rogg H, Brunner H: β-adrenoceptor antagonists in hypertension. In: Scriabine A (ed) Pharmacology of antihypertensive drugs. Raven Press, New York, 1980; 179–194.Google Scholar
  3. 3.
    Berglund G, Wilhelmsen L, Sannerstedt R, Hansson L, Andersson O, Sivertsson R, Wedel H, Wikstrand J: Coronary heart disease after treatment of hypertension. Lancet 1978; 1: 1–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Steward IMG: β-adrenoceptor blockade and the incidence of myocardial infarction during treatment of severe hypertension. Br Clin Pharmacol 1982; 13: 91–93.Google Scholar
  5. 5.
    Trafford JAP, Horn CR, O’Neal H, McGonigle R, Halford-Maw L, Evans R: Five years follow-up of effects of treatment of mild and moderate hypertension. Br Med J 1981; 282: 1111–1113.CrossRefGoogle Scholar
  6. 6.
    Beevers DG, Johnston JG, Larkin H, Davies P: Clinical evidence that β-adrenoceptor blockers prevent more cardiovascular complications than other antihypertensive drugs. Drugs, 1983; 25 (Suppl 2): 326–330.CrossRefGoogle Scholar
  7. 7.
    Scriabine A: β-adrenoceptor blocking drugs in hypertension. Ann Rev Pharmacol Toxicol 1979; 19: 269–284.CrossRefGoogle Scholar
  8. 8.
    Opie LH: Drugs and the heart. I β-blocking agents. Lancet 1980; 1: 693–698.PubMedGoogle Scholar
  9. 9.
    Frishman WH: β-adrenoceptor antagonists: New drugs and new indications. N Engl J Med 1981; 305: 500–506.PubMedCrossRefGoogle Scholar
  10. 10.
    Robertson JIS: State of the art review: β-blockade and the treatment of hypertension. Drugs, 1983; 25 (Suppl 2): 5–11.CrossRefGoogle Scholar
  11. 11.
    Woods PB, Robinson ML: An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J Pharm Pharmacol 1981; 33: 172–173.PubMedCrossRefGoogle Scholar
  12. 12.
    Johnson G, Regards CG: Clinical pharmacokinetics of β-adrenoceptor blocking drugs. Clin Pharmacol 1976; 1: 233–263.CrossRefGoogle Scholar
  13. 13.
    Frishman W: Clinical pharmacology of the new β-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J 1979; 97: 663–670.PubMedCrossRefGoogle Scholar
  14. 14.
    George GF: Pharmacodynamics and pharmacokinetics of cardiovascular drugs. In: Coltart J, Jewitt D (eds) Recent developments in cardiovascular drugs. Churchill Livingstone, Edinburgh, 1982; 16$27.Google Scholar
  15. 15.
    Shand DG: State of the art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs 1983; 25 (Suppl 2): 92–99.CrossRefGoogle Scholar
  16. 16.
    Powel CE, Slater IH: Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther 1958; 122: 480–488.Google Scholar
  17. 17.
    Kaumann AJ: Herz β-Rezeptoren. Experimentelle Standpunkte. Z Kardiol 1983; 72: 63–82.PubMedGoogle Scholar
  18. 18.
    Langer SZ, Cavero I, Massingham B: Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 1980; 2: 373–382.Google Scholar
  19. 19.
    Tackett RL, Webb IG, Privitera PJ: Cerebroventricular propanolol elevates cerebrospinal fluid norepinephrine and lowers arterial pressure. Science 1981; 213: 911–913.PubMedCrossRefGoogle Scholar
  20. 20.
    Cruickshank JM: How safe are the β-blockers? Drugs 1983; 25 (Suppl 2): 331–340.CrossRefGoogle Scholar
  21. 21.
    Breckenridge A: Which β-blocker? Br Med J 1983; 286: 1085–1088.CrossRefGoogle Scholar
  22. 22.
    Gallery EDM, Saunders DM, Hunyor SN, Gyory AZ: Randomized comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. Br Med J 1979; 1: 1591–1594.PubMedCrossRefGoogle Scholar
  23. 23.
    Rubin PC, Butters L, Clark DM et al.: Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 1983; 1: 431–434.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • E. Alegría Ezquerra
  • J. A. Arrieta
  • R. Huguet
  • J. Barba
  • D. Martinez-Caro

There are no affiliations available

Personalised recommendations